FDA believes it is critically important to ensure that the promotional messages companies use to introduce new drugs are accurate and balanced as these messages form the public’s first impression of new drugs.
Similar Posts
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem celCOSMO KOREA – 11/03/2025
Unapproved New Drugs/Misbranded/BotoxGeneric Drug Research Collaboration Opportunities
The Office of Generic Drugs implements the GDUFA Regulatory Science Research Program by collaborating through grants or contracts.Newly Added Guidance Documents
Guidance documents represent the FDA’s current thinking on a particular subject. New guidance documents are listed here for three months.Catalent Indiana, LLC – 718189 – 11/20/2025
CGMP/Finished Pharmaceuticals/Adulteratedwww.usaquickmeds.com – 713312 – 08/01/2025
Misbranded and Unapproved New Drugs